

Resource Summary Report

Generated by [RRID](#) on Aug 31, 2026

RPMI-8226/MR20

RRID:CVCL_0509

Type: Cell Line

Proper Citation

RRID:CVCL_0509

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0509

Proper Citation: RRID:CVCL_0509

Description: Cell line RPMI-8226/MR20 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Plasma cell myeloma

Defining Citation: [PMID:10070958](#), [PMID:10825126](#), [PMID:11309308](#), [PMID:12116365](#)

Comments: Characteristics: Produces IgG lambda (from parent cell line RPMI-8226/MR4)., Population: African American.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: RPMI-8226/MR20

Synonyms: RPMI 8226/MR20, RPMI8226/MR20, 8226/MR20, 8226 MR20

Cross References: MCCL:MCC:0000407, cancercellines:CVCL_0509, Wikidata:Q54951250

ID: CVCL_0509

Hierarchy: cvcl_4v90

Record Creation Time: 20220427T221507+0000

Record Last Update: 20260829T235800+0000

Ratings and Alerts

No rating or validation information has been found for RPMI-8226/MR20.

No alerts have been found for RPMI-8226/MR20.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Cholujova D, et al. (2026) Anti-myeloma activity of the CXCR4 antagonist WZ811. Journal of molecular medicine (Berlin, Germany), 104(1), 45.